Docket #: S19-533
Use of Small Molecule Inhibitor for Preventing Abdominal Adhesions
Researchers at Stanford have identified a novel method of use for the drug T-5224 in the prevention of abdominal adhesion. Using a mouse model of abdominal adhesions, the researchers found that local application of T-5224 inhibits adhesion formation in vivo, with no negative side effects observed. Today, there are essentially no available treatments to prevent adhesions, which are fibrotic scars that form between abdominal organs following surgery or infection, and cause bowel obstruction, chronic pain, or infertility. Adhesions occur post-operatively in 50- 90% of all open abdominal operations, representing an enormous clinical problem impacting hundreds of millions of patients worldwide. T-5224 is a small molecule inhibitor of the Activator Protein 1 (AP-1) transcription factor complex, and has previously been shown to decrease fibrosis in models of systemic sclerosis as well as to attenuate LPS-induced liver injury and endotoxin-induced kidney injury. The new findings suggest that T-5224 should be explored clinically as a novel agent for adhesion prevention; for example, in patients undergoing abdominal surgical operations.
Stage of Development
Research – in vivo.
Applications
- Prevention of abdominal adhesions in patients following surgical operations or intra-abdominal infection
- In the treatment of other peritoneal diseases related to fibrosis (e.g., peritoneal carcinomatosis)
- Fibrosis elsewhere in the body (e.g., prevention of pleural or pericardial fibrosis in the context of surgical procedures in the chest or prevention of adhesions after tendon repairs)
Advantages
- These findings represent a significant advancement in the prevention of abdominal adhesions
- No comparable therapy currently exists
- Potential for immense improvement in clinical care
Publications
- Foster, D.S., Marshall, C.D., Gulati, G.S. et al. "Elucidating the fundamental fibrotic processes driving abdominal adhesion formation." Nat Commun 11, 4061 (2020).
Related Technology
Docket #: S23-384: Encapsulation and Local Delivery of Inhibitors of the Activator Protein 1 (AP-1) for Preventing Adhesions
Related Links
Patents
- Published Application: WO2021257887
- Published Application: 20230241035
Similar Technologies
-
Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury S21-314Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
-
Encapsulation and Local Delivery of Inhibitors of the Activator Protein 1 (AP-1) for Preventing Adhesions S23-384Encapsulation and Local Delivery of Inhibitors of the Activator Protein 1 (AP-1) for Preventing Adhesions
-
Use of Focal Adhesion Kinase Inhibitors To Reduce Scar Formation In Combination With Split Thickness Skin Grafts S21-198Use of Focal Adhesion Kinase Inhibitors To Reduce Scar Formation In Combination With Split Thickness Skin Grafts